Maryland Will Target Lower Drug Prices in 2027
Governor Wes Moore plans to introduce legislation in January 2027 to cap costs for 23 essential medications.
Updated on Oct. 14, 2026 in Diabetes
Live Poll
Should your state government intervene to lower prescription drug costs for residents?
Maryland Governor Wes Moore intends to champion new legislation in January 2027 that authorizes the state's Prescription Drug Affordability Board to match federal Medicare drug prices. The bill seeks to lower costs for 23 medications treating conditions such as diabetes, asthma, and cancer.
Why it matters
This initiative aims to improve financial access to critical treatments by leveraging federal price negotiations at the state level. The state is currently evaluating potential patient savings across 25 different drug products to guide the policy's implementation.
The proposed legislation covers 23 specific medications under the state board's authority, while analysts are currently reviewing 25 drugs to determine potential patient savings.
The players
Wes Moore
Wes Moore is the Governor of Maryland who plans to sign the drug pricing legislation into law.
Prescription Drug Affordability Board
The Prescription Drug Affordability Board is a Maryland state entity tasked with managing prescription price caps.
The details
The state Prescription Drug Affordability Board already maintains matching authority for Jardiance and Ozempic, but the new law would expand this to a broader list of chronic conditions. Maryland health officials are specifically targeting treatments for heart issues and kidney disease alongside other common ailments.
Timeline
The legislative session begins in January 2027.
Health Landscape
Maryland's legislative push follows the implementation of the federal Medicare drug-price negotiation provisions. This move marks a significant expansion of state-level oversight in healthcare markets by mirroring federal pricing mechanisms.
Residents may see lower out-of-pocket costs for essential medications if the bill succeeds in matching Medicare pricing benchmarks. This change could simplify access to treatments for those managing conditions like diabetes, heart disease, or asthma.
The takeaway
Patients who rely on high-cost prescription drugs should monitor the legislative developments in 2027 to see if their specific medications fall under the new state price caps. Staying informed about state-level drug pricing changes can help households better anticipate shifts in monthly healthcare expenses.
Further reading
For more information on ongoing state efforts to manage chronic condition costs, visit Maryland Diabetes.
Source note: This article includes information reported by WBAL.
Live Poll
Should your state government intervene to lower prescription drug costs for residents?
